About
Optogenetics
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
870
By Phase
PHASE2: 4
By Status
RECRUITING: 3ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06887192Lead Sponsor
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
PHASE2Recruiting
300 participants
Started: Aug 15, 2025 · Completed: Feb 28, 2027
NCT07038876Lead Sponsor
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
PHASE2Recruiting
300 participants
Started: Jun 27, 2025 · Completed: Jan 31, 2027
NCT05889273Lead Sponsor
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
PHASE2Enrolling by invitation
120 participants
Started: Jun 1, 2023 · Completed: Dec 31, 2027
NCT05081245Lead Sponsor
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
PHASE2Recruiting
150 participants
Started: Sep 13, 2022 · Completed: Nov 30, 2026
Locations (1)
Headquarters
Burlington, MA, United States
Map
Loading map...